secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001193125-24-064791
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ACAD's Phase 3 ADVANCE-2 trial of pimavanserin misses primary endpoint in negative symptoms of schizophrenia
--------------------------------------------------------------------------------

- Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.
- Safety and tolerability consistent with prior trials, showing low adverse event rate.
- No financial or regulatory guidance provided in this 8-K; further analysis may follow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524064791/0001193125-24-064791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524064791/d786050d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-064791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer